Perspective Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $81 | $76 | $43 | $209 |
Gross Profit | 81 | -1,050 | -968 | -566 |
EBITDA | -26,716 | -27,155 | -37,208 | -25,129 |
EBIT | 3,401 | -28,281 | -38,219 | -25,904 |
Net Income | -26,786 | -26,189 | -37,490 | -25,969 |
Net Change In Cash | 81 | 76 | 43 | 209 |
Free Cash Flow | -34,845 | -38,326 | -29,732 | -18,284 |
Cash | 48,488 | 53,972 | 30,629 | 26,762 |
Basic Shares | 73,813 | 73,813 | 74,341 | 74,296 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 |
|---|---|---|---|---|
Revenue | $884 | $1,454 | $1,434 | $7,104 |
Gross Profit | -2,367 | -852 | 1,434 | 1,634 |
EBITDA | -100,801 | -64,491 | -39,960 | -14,838 |
EBIT | -104,052 | -66,797 | -40,941 | -15,182 |
Net Income | -103,121 | -79,279 | -46,508 | -14,670 |
Net Change In Cash | 884 | 1,454 | 1,434 | 7,104 |
Free Cash Flow | -95,233 | -72,708 | -37,985 | -12,474 |
Cash | 30,629 | 61,580 | 9,238 | 20,993 |
Basic Shares | 73,813 | 64,425 | 54,905 | 142,103 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.22 |
2026-03-31 | -$0.25 |
2025-12-31 | -$0.50 |
2025-09-30 | -$0.35 |